+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Company Analysis: Merck & Co

  • ID: 5357324
  • Company Profile
  • January 2021
  • 80 pages
  • Datamonitor Healthcare
  • Merck & Co., Inc.
The publisher explores Merck & Co’s prescription pharmaceutical performance and outlook over 2019-29.
Snapshot
  • Overview - Merck & Co’s revenue growth will be fairly stable over the forecast period, as growth from Keytruda and Gardasil will be offset by declines from Januvia, Janumet, and the spin-off of Women’s Health and Legacy Brands.
  • Key themes - [1] Keytruda will see strong growth over the forecast period until loss of exclusivity in 2028, although 2020 growth will be negatively impacted by two large price reductions in Japan [2] Merck’s metabolic portfolio will decline significantly due to patent expiries for key drugs Januvia and Janumet [3] Merck’s late-stage pipeline is heavily skewed towards label expansions for its existing oncology portfolio, with only a few new drug launches expected over the forecast period.
Model updates (27 October 2020)
  • Keytruda forecast adjusted higher in the US due to lower impact from COVID-19 and broadening of revenue base beyond lung cancer
  • Gardasil forecast adjusted lower due to continued COVID-19 impact in the US
  • Januvia forecast adjusted higher due to stronger revenue trends.
Model updates (3 August 2020)
  • Gardasil forecast adjusted lower due to COVID-19 impact in the US
  • ProQuad forecast adjusted lower due to COVID-19 impact in the US
  • Pneumovax 23 forecast adjusted lower due to COVID-19 impact in the US
  • Keytruda forecast adjusted lower due to COVID-19 impact in the US and Europe.
Model updates (2 June 2020)
  • Lenvima alliance revenue forecast adjusted higher
  • NuvaRing forecast adjusted lower due to generic impact in the US.
Model updates (4 March 2020)
  • Keytruda forecast adjusted lower due to 2020 impact of two significant price reductions in Japan
  • Gardasil forecast adjusted higher due to strong demand globally
  • Lenvima alliance revenue forecast added
  • Lynparza alliance revenue forecast added
  • Zetia forecast removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
  • Vytorin removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
  • NuvaRing removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
  • Implanon removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
  • Singulair removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
  • Cozaar removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
  • Nasonex removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
  • Arcoxia removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
  • Follistim removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands.
Note: Product cover images may vary from those shown
Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison
Recent Earnings Review
  • Earnings Overview
  • Pharma Insights Analysis
Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis
Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights
Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug
Note: Product cover images may vary from those shown
Adroll
adroll